Successful DHL trial

Timestrip PLC
21 November 2007



TIME.L

                                 Timestrip plc

                  DHL successfully trial Timestrip and iStrip

Timestrip plc is pleased to announce that its Timestrip and iStrip label
technologies have been successfully trialled in a pilot project with DHL, one of
the world's leading logistics companies, to monitor temperatures of sensitive
products such as medical vaccinations during transportation.

The iStrip is a patent pending label developed by Timestrip plc which undergoes 
an irreversible colour change when exposed to freezing temperatures.  It is 
designed to be mass-produced at low cost and to be fully integrated into the 
packaging of products such as vaccines, protein based pharmaceuticals, 
foodstuffs and fertilizer.

The trial was focused on improving the transportation of sensitive products in 
order to ensure that the correct temperature conditions were maintained 
throughout the critical storage and transportation process.  Correct storage 
temperatures are key to this process as up to 50% of problems with the 
transportation of medical health care products for example are due to incorrect 
storage temperatures.

The DHL project has successfully demonstrated the benefit of the Timestrip and 
iStrip technologies, not only in monitoring optimum transport temperatures but 
also in identifying, when problems do occur, which particular parts of a pallet 
or shipment have been adversely affected.  This allows targeted disposal of 
affected products, reducing the need to destroy a product that may be scarce or 
valuable.


Commenting on the trial, Mike Meakin, Quality Director, Healthcare EMEA, DHL 
Exel said:

'One of the biggest challenges currently facing logistics companies is 
temperature assurance in frozen, chilled and temperate conditions.  It is now 
clear that we can use Timestrip and iStrip labels to highlight whether a 
temperature limit could have been breached.  As a consequence, we have been able 
to find a cost-effective way to enhance quality assurance.'

Reuben Isbitsky, Joint CEO of Timestrip plc, said:

'We are delighted to have been involved in this pilot trial with DHL that has 
confirmed the unique and far-reaching benefits that our label technologies can 
bring to companies transporting pharmaceutical and related healthcare products.  
I look forward to being able to announce further details of developments with 
DHL in the future.'


For more information, please contact:

Paul Freedman/Reuben Isbitsky, Joint CEOs, Timestrip plc           01462 440 700
Shane Dolan, Biddicks                                              020 7448 1000
Fergus Marcroft, Evolution Securities                              020 7071 4300




                      This information is provided by RNS
            The company news service from the London Stock Exchange